Document:

Exhibit 10.28

 

Certain personally identifiable information contained
in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K.

 

Loan Agreement

 

of October 15, 2021

 

between

 

		1.	Biotechnology Value Fund, L.P.

44 Montgomery Street, 40th
Floor

San Francisco, CA 94104, USA

[***]

(hereinafter
“Lender 1”)

 

		2.	Biotechnology Value Fund II, L.P.

44 Montgomery
Street, 40th Floor

San Francisco,
CA 94104, USA

[***]

(hereinafter “Lender
2”)

 

		3.	Biotechnology Value Trading Fund OS, L.P.

PO Box 309 Ugland House,
Grand Cayman

KY1-1104, Cayman
Islands

[***]

(hereinafter “Lender
3”)

 

(each a “Lender”
and collectively the “Lenders”)

 

and

 

		4.	MoonLake Immunotherapeutics AG

c/o KD Zug-Treuhand
AG

Untermüli
7

6302 Zug, Switzerland

		[***]	

(hereinafter
the “Borrower”)

 

(the Lenders, the Borrower each a
“Party” and collectively the “Parties”)

 

     

    

    

 

Loan Agreement

 

 

TAble of contents

 

	Preamble	2
	 	 	 
	1.	Definitions	2
	 	 	
	2.	Loans	2
	 	 	 
	3.	Interest	2
	 	 	 
	4.	Disbursement	2
	 	 	 
	5.	Purpose	2
	 	 	 
	6.	Term
    and Repayment	3
	 	 	 
	7.	Events
    of Default	3
	 	 	 
	8.	Security	3
	 	 	 
	9.	Representations
    and Warranties	4
	 	 	 
	10.	Covenants	4
	 	 	 
	11.	Status
    and Subordination	5
	 	 	 
	12.	Miscellaneous	6
	 	 	 
	13.	Applicable
    law and jurisdiction	9
	 	 	 
	Annex
    1: Definitions	11

 

    i

     

    

 

Loan Agreement

 

 

		Preamble	

 

		A.	The Borrower is organized in the form of a Swiss stock corporation (Aktiengesellschaft) registered
with the commercial register of the Canton of Zug under the number CHE-433.093.536.

 

		B.	The Borrower’s core business is the research, development, manufacturing and marketing of biotechnological,
pharmaceutical and similar products in Switzerland and abroad.

 

		C.	The Borrower has an issued statutory share capital in the nominal amount of CHF 104,072.50, divided
into 1,040,725 fully paid-in registered shares with a nominal value of CHF 0.10 each, of which 360,529 are common shares (Stammaktien)
and 680,196 are series A preferred shares (Vorzugsaktien Kategorie A) (such shares, together with any shares of the Borrower issued
after the date of this Agreement, the “Shares”). The Borrower also has conditional share capital to support issuances
under the employee equity incentive plans allowing an increase of the nominal share capital by a maximum amount of CHF 2,947.10 by
issuing a maximum of 29,471 registered common shares.

 

		D.	On October 4, 2021, the Borrower entered into a business combination agreement, with Helix Acquisition
Corp. (“Helix”) and the shareholders of the Borrower; a subscription agreement with Helix, an investment agreement
with Helix and the shareholders of the Borrower, a restated and amended shareholders’ agreement with Helix and the shareholders
of the Borrower and certain other agreements in connection therewith (the “Transaction”). The Borrower currently requires
bridge financing in order to finance its business operations.

 

		E.	Therefore, the Borrower has proposed to the Lenders, the issuance of one or several subordinated loans
in an aggregate amount of USD 15,000,000 on the basis of identical principal terms and conditions (the “Financing Round”).

 

		F.	As part of the Financing Round, the Lenders intend to issue to the Borrower subordinated loans on the
basis of the terms and conditions set out in this Agreement.

 

    1

     

    

 

Loan Agreement

 

  

Now, therefore,
the Parties agree as follows:

 

		1.	Definitions

 

Capitalized terms used in this Agreement
shall have the meaning as set forth in Annex 1.

 

		2.	Loans

 

Subject to the terms of this Agreement,
each of the Lenders hereby grants to the Borrower a loan (each a “Loan” and collectively the “Loans”)
in the nominal amount stated in the table below (each a “Principal Amount” and collectively the “Principal
Amounts”).

 

	Lender	 	Principal Amount in USD	 
	Lender 1	 	 	8,139,000	 
	Lender 2	 	 	5,946,000	 
	Lender 3	 	 	915,000	 
	TOTAL	 	 	15,000,000	 

 

		3.	Interest

 

The Loans shall be interest-free.

 

		4.	Disbursement

 

Disbursement of the Loans by the Lenders
shall be effected in one tranche as follows:

 

		●	a tranche in the aggregate amount of USD 15,000,000 within 48 hours of the date of this Agreement.

 

The Lenders shall disburse the Loans
to the bank account of the Borrower as notified to the Lenders for such purposes, free of any costs or charges.

 

		5.	Purpose

 

The Loans may be used for the financing
of general corporate purposes of the Borrower, including product and technology development, operations, sales and marketing, management
expenses, and salaries.

 

    2

     

    

 

Loan Agreement

 

  

		6.	Term and Repayment

 

The Loans granted hereunder are granted
for a fixed period of time until the earlier of (i) the Transaction Closing and (ii) February 15, 2022 (the “Maturity Date”).

 

The Loans may be repaid in whole or
in part by the Borrower at any time or prior to the Maturity Date.

 

		7.	Events of Default

 

On and at any time after the occurrence
of any of the events listed hereafter (an “Event of Default”), but subject to any suspensive effect resulting from
the subordination pursuant to Section 11, the Lender Majority may (but is not obliged), by notice to the Borrower, declare that all or
part of the Loan Balance become due and payable within 30 calendar days of receipt of such notice by the Borrower:

 

		a)	Illiquidity: the Borrower is unable or admits inability to pay its debts as they fall due, suspends making
payments on any of its debts or, by reason of actual or anticipated financial difficulties, commences negotiations with one or more of
its creditors with a view to rescheduling any of its indebtedness;

 

		a)	Insolvency: the Borrower is declared bankrupt by a court, applies for bankruptcy (Konkurs) or reorganization
(Nachlassstundung), or has a resolution passed for its winding-up, a creditor files a petition for bankruptcy (Fortsetzungsbegehren)
or any similar event or such event is immediately threatened;

 

		b)	Breach of Representations and Warranties: any representation or warranty set forth in Section 9 proves
to have been inaccurate or misleading in any material respect;

 

		c)	Breach of Covenant: the Borrower breaches any of the covenants set forth in Section 10 and the consequences
of such breach are not fully cured within 30 calendar days from the date of receipt of a respective notice by the Borrower from the Lenders;
or

 

		d)	Change of Control: the Borrower consummates a Change of Control at any time while the Loans remain outstanding.

 

		8.	Security

 

The Loans shall not be secured.

 

    3

     

    

 

Loan Agreement

 

  

		9.	Representations and Warranties

 

		9.1	Borrower

 

The Borrower, as per the date of this
Agreement, hereby represents and warrants to the Lenders as follows:

 

		a)	the Borrower is a company duly incorporated and validly existing under the laws of Switzerland, and has
full power, authority and legal right to own its assets, to carry on its business as it is being conducted and to enter into and perform
its obligations under this Agreement;

 

		b)	the execution, delivery and performance by the Borrower of this Agreement (i) have been duly authorized
by all necessary corporate decisions and other measures, (ii) require no governmental or regulatory action, authorization or approval,
(iii) do not and will not violate or conflict with the provisions of the articles of incorporation or by-laws of the Borrower and (iv)
do not and will not result in a breach of or constitute a default under any agreement or obligation applicable to the Borrower or by which
the Borrower is bound;

 

		c)	the obligations of the Borrower under this Agreement constitute legal, valid and binding obligations of
the Borrower, enforceable in accordance with their terms; and

 

		d)	no Event of Default has occurred.

 

		10.	Covenants

 

The Borrower hereby covenants and
agrees vis-à-vis the Lenders, that it:

 

		a)	shall not grant, create or permit to subsist any security interest, including personal securities (Personalsicherheiten)
such as a surety and guarantee, over any of its present or future assets or revenues, except for security interests arising by operation
of law or in the ordinary course of business;

 

		b)	shall not request the distribution of dividends or other distributions to shareholders (it being understood
that the power to set or not set the dividends lies inalienably with the general meeting of the shareholders); and

 

		c)	shall comply with all material laws and regulations applicable to the Borrower in all material respects.

 

    4

     

    

 

Loan Agreement

 

  

		11.	Status and Subordination

 

Subject to the terms in this Section
13, the claims of the Lenders against the Borrower under, the Loans shall rank pari passu without discrimination or preference
with other unsecured subordinated obligations of the Borrower, except for the claims of Borrower’s creditors whose claims are mandatorily
preferred by laws of general application.

 

Each of the Lenders hereby irrevocably
and unconditionally declares to the Borrower that their claims with respect to Loan Balance owed now or in the future (the “Relevant
Subordinated Claims”), shall be and is hereby subordinated to all current and future claims of creditors of the Borrower.

 

During such term the Relevant Subordinated
Claims shall be deferred (gestundet) and none of the Relevant Subordinated Claims may neither fully nor partially be repaid, set-off,
novated or otherwise be fulfilled and no security interest may be created in relation to such claims. The Relevant Subordinated Claims
shall be listed separately in the financial statements of the Borrower. If the Borrower is declared bankrupt by a court or if the Borrower
makes a general assignment, arrangement or composition with or for the benefit of its creditors, the Lenders herewith waive their Relevant
Subordinated Claims to the extent required to cover from the liquidation proceeds the claims of the other creditors and the claims arising
in connection with the liquidation procedure.

 

In the case of bankruptcy or debt
restructuring liquidation of one or more Lenders, the Borrower is permitted to offset the Relevant Subordinated Claims of such Lenders
with the Borrower’s claims against it/them.

 

The Lenders acknowledge and agree
that nothing in this Agreement shall be construed as to restrict the board of directors of the Borrower to notify the competent courts
in case of an equity shortfall in the sense of Article 725 para. 2 CO.

 

The subordination pursuant to this
Agreement shall automatically be terminated if any of the following events occur:

 

		a)	the Lender Majority and the Borrower agree that the subordination be cancelled, provided, however, that
such an agreement shall only be effective and binding upon the Parties, if financial statements of the Borrower which (i) are not older
than 6 months and (ii) audited in accordance with the then current Swiss Audit Standards (Schweizer Prüfungsstandards) show
that all liabilities of the Borrower (including the amounts owed by the Borrower under the Relevant Subordinated Claims and all other
subordinated liabilities, if any) are sufficiently covered by assets (in case the Borrower is subject to a full audit (ordentliche
Revision), a summarizing audit report from the auditor without a qualification in the sense of Article 725 para. 2 CO suffices to
satisfy this requirement); or

 

    5

     

    

 

Loan Agreement

 

  

		b)	the Lenders irrevocably waive any and all Relevant Subordinated Claims.

 

The subordination pursuant to this
Agreement has been approved by the board of directors of the Borrower having given due consideration to the creditworthiness of the Lenders.
The Lenders confirm that sufficient net wealth is at their disposal to absorb a possible or complete loss of the Relevant Subordinated
Claims.

 

		12.	Miscellaneous

 

		12.1	Nature of Parties’ Rights and Obligations

 

Except as specifically provided otherwise
in this Agreement, the rights and obligations of the Parties hereunder shall be several (and not joint). Each of the Parties may exercise
and enforce their rights hereunder individually in accordance with this Agreement, and the non-performance by a Party shall not relieve
any other Party from performing its obligations under this Agreement, nor shall the non-defaulting Parties be liable for the non-performance
by the defaulting Party.

 

The obligations of the Parties hereunder
are contractual in nature and the Parties agree that they do not form, and this Agreement shall not be deemed to constitute, a simple
partnership pursuant to Art. 530 et seq. CO.

 

The Loans do not form, and they shall
not be deemed to constitute, a bond (Anleihensobligation) pursuant to Art. 3 lit. a no. 7 FinSA and/or Art. 1156 et seq. CO.

 

		12.2	Confidentiality

 

Each of the Parties agrees to keep
secret and confidential and not to use, disclose or divulge to any third party or to enable or cause any person to become aware of, any
of the terms and conditions of this Agreement, and any information exchanged among the Parties in connection with the investment in the
Borrower or pertaining to the business and the operation of the Borrower (all such information collectively “Confidential Information”).
The Parties shall ensure that their employees, directors and any other representatives as well as the advisors of each Party to whom any
such Confidential Information is entrusted comply with these restrictions.

 

    6

     

    

 

Loan Agreement

 

  

The term Confidential Information
shall not include any information (i) which as of the time of its disclosure by a Party was already lawfully in the possession of the
receiving Party as evidenced by written records, or (ii) which at the time of the disclosure was in the public domain, or (iii) the disclosure
of which was previously explicitly authorized by the respective Party.

 

The non-disclosure obligation shall
not apply to any disclosure of Confidential Information required by law or regulations. In the event a disclosure of Confidential Information
is required by law or regulations (including, without limitation, for tax, audit or regulatory purposes), the disclosing Party shall use
all reasonable efforts to arrange for the confidential treatment of the materials and information so disclosed.

 

Each Party may use any Confidential
Information in accordance with this Agreement. But, subject to the terms hereof, each Party acknowledges and agrees that any Confidential
Information made available to it (including to any representative or advisor of such Party) by the Borrower or any other Party (including
their representatives or advisors) hereunder shall not be used by such Party other than (i) as permitted under this Agreement, (ii) for
the benefit of the Borrower, or (iii) for the respective Party’s assessment of the Borrower, and shall not be exploited by or for
the benefit of such Party or any of its Affiliates or third party.

 

It is acknowledged and agreed that
the Lenders may report regularly to its investors and/or any of its Affiliates on information pertaining to the Borrower and the equity
investment made or to be made in the Borrower in accordance with its reporting obligations under its fund investment documents or to the
extent required for legal, tax, audit or regulatory purposes.

 

Nothing herein shall restrict (i)
the Borrower from granting third parties customary due diligence access for purposes of financial, commercial, strategic or similar transactions
(including for a subscription of Shares in the Borrower) or (ii) the Lenders or any shareholder from disclosing this Agreement to third
parties (other than competitors of the Borrower) being interested in good faith in an assignment of a Loan or an acquisition of Shares,
provided, however, that such disclosure is based on appropriate non-disclosure and non-use agreements.

 

    7

     

    

 

Loan Agreement

 

  

		12.3	Successors and Assigns

 

This Agreement shall be binding upon
and shall inure to the benefit of the Parties and their respective permitted successors and assigns, provided, however, that neither Party
shall be entitled to assign or transfer any of the rights or obligations hereunder to any other party.

 

		12.4	Costs and Expenses

 

Each Party shall bear its own costs
and expenses arising out of or incurred, and any taxes and fees imposed on it, in connection with this Agreement and all transactions
contemplated hereby.

 

		12.5	Notices

 

All notices and other communications
made or to be made under this Agreement shall be given in writing or electronic form and be delivered by post, courier or email to the
addresses indicated on the cover sheet, unless otherwise notified by a Party.

 

For the purpose of meeting a period
or deadline by the sender, a notice shall be deemed made when dispatched by the sender. For the purpose of triggering the start of a period
or deadline for the recipient, a notice shall be deemed made or received when it arrives at the recipient.

 

		12.6	Entire Agreement

 

This Agreement constitutes the entire
agreement among the Parties with respect to the subject matter hereof and supersedes any agreement or understanding with respect to the
subject matter hereof that may have been concluded between the Borrower and the Lenders prior to the date of this Agreement.

 

		12.7	Severability

 

If at any time any provision of this
Agreement or any part thereof is or be-comes invalid or unenforceable, then neither the validity nor the enforceability of the remaining
provisions or the remaining part of the provision shall in any way be affected or impaired thereby. The Parties agree to replace the invalid
or unenforceable provision or part thereof by a valid or enforceable provision, which shall best reflect the Parties’ original intention
and shall to the extent possible achieve the same economic result.

 

    8

     

    

 

Loan Agreement

 

  

		12.8	Amendments

 

The Parties acknowledge and agree
that this Agreement may be amended by an instrument signed or a resolution approved by the Borrower and the Lender Majority, provided,
however, that any such modification or amendment of any of the provisions of this Agreement shall neither affect any accrued rights of
any other Lender nor impose any greater liability or any more onerous obligation than those contained in this Agreement on the other Lenders
who do not sign such modification or amendment.

 

		12.9	Disclaimer

 

The Lenders hereby acknowledge that
the Borrower is not subject to oversight by the Swiss Financial Market Supervisory Authority FINMA and the Loans are not protected by
the deposit protection rules pursuant to Art. 37h et seq. SBA.

 

		12.10	Form Requirements

 

This Agreement may be executed and
amended in writing or in electronic form (such as Skribble, DocuSign or AdobeSign, or which contains an electronic scan of the signature)
and be delivered by post, courier or email; the counterpart so executed and delivered shall be deemed to have been duly executed and validly
delivered and be valid and effective for all purposes.

 

		13.	Applicable law and jurisdiction

 

This Agreement shall in all respects
be governed by and construed in accordance with Swiss law under the exclusion of its private international law provisions and international
treaties.

 

Any dispute, controversy or claim
arising out of, or in relation to, this con-tract, including the validity, invalidity, breach, or termination thereof, shall be subject
to the exclusive jurisdiction of the courts of Zug, Canton of Zug, Switzerland.

 

[signature page to follow]

 

    9

     

    

 

Loan Agreement

 

  

	Lender 1	 
	 	 
	Signature:	/s/ Mark Lampert
	 	 
	Name:	Mark Lampert
	Title:	Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.
	 	 
	Lender 2	 
	 	 
	Signature:	/s/ Mark Lampert
	 	 
	Name:	Mark Lampert
	Title:	Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P.
	 	 
	Lender 3	 
	 	 
	Signature:	/s/ Mark Lampert
	 	 
	Name:	Mark Lampert
	Title:	President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.
	 	 
	Borrower	 
	 	 
	MoonLake Immunotherapeutics AG
	 	 
	Signature:	/s/ Jorge Santos da Silva
	Name:	Dr. Jorge Santos da Silva 
	Title:	Chief Executive Officer
	 	 
	Signature:	/s/ Matthias Bodenstedt
	Name:	Matthias Bodenstedt 
	Title:	Chief Financial Officer

 

    10

     

    

 

Loan Agreement

 

  

Annex 1: Definitions

 

	Affiliates	shall mean any individual, firm, corporation, partnership, association, limited liability company, trust or any other entity that:
	 	 
		a)

                           

                           

                          b)

                          

                          

                          
	
    directly
or indirectly is controlled by or is under common control with a Party;

     

     directly
    or indirectly controls a Party;

    

	 	 	 
	 	including, without limitation, any venture capital fund or registered investment company now or hereafter existing that is managed or advised by such Party or by the same advisor as such Party, provided, however, that the ultimate beneficial owner(s) of such Party remains at all times the ultimate beneficial owner(s) of the relevant individual, firm, corporation, partnership, association, limited liability company, trust or other entity.

 

	Agreement	shall mean this loan agreement, including its Annexes and related documents, as amended from time to time.
	 	 
	Annex	shall mean an annex to this Agreement.
	 	 
	Borrower	shall have the meaning given on the cover page of this Agreement.

 

	Change of Control	shall mean:

	 	 
	 	a)	the
    acquisition of more than 50% of the Borrower’s outstanding Shares by any person or entity in any transaction or series of related
    transactions (other than as a result of bona fide equity financing purposes (including, but not limited to the Transaction Closing));
    or
	 	 	 
	 	b)	a
    merger, spin-off or other type of restructuring in which the holders of the voting securities of the Borrower outstanding immediately
    prior to such transaction retain less than the majority of the total voting power represented by the voting securities of the Borrower
    or such surviving entity outstanding immediately after such transaction; or

 

    11

     

    

 

Loan Agreement

 

  

	 	c)	a
    sale, lease, transfer, exclusive license or other conveyance of all or substantially all of the assets of the Borrower in an arms’
    length transaction (other than to a wholly-owned subsidiary of the Borrower or to a parent Borrower).

 

	CO	shall mean the Swiss Code of Obligations of 30 March 1911, as amended.
	 	 
	Confidential Information	shall have the meaning ascribed to it in Section 12.2.
	 	 
	Event of Default	shall have the meaning ascribed to it in Section 7.
	 	 
	Financing Round 	shall have the meaning given in Section E of the Preamble.
	 	 
	FinSA	shall mean the Swiss Financial Services Act of 15 June 2018, as amended.
	 	 
	Helix	shall have the meaning given in Section D of the Preamble.
	 	 
	Lender Majority	shall mean one or several Lenders holding in aggregate more than 50% in nominal value of the Principal Amounts.
	 	 
	Lenders	shall have the meaning given on the cover page of this Agreement.
	 	 
	Loan Balance	shall mean, with respect to each Loan, the Principal Amounts together with all other amounts accrued or outstanding under this Agreement, if any, at the relevant calculation date. 
	 	 
	Loan(s)	shall have the meaning ascribed to it in Section 2.
	 	 
	Maturity Date	shall have the meaning ascribed to it in Section 6.
	 	 
	Party/Parties	shall have the meaning given on the cover page of this Agreement.
	 	 
	Preamble	shall mean the preamble of this Agreement. 
	 	 
	Principal Amount(s)	shall have the meaning ascribed to it in Section 2.
	 	 
	Relevant Subordinated Claims	shall have the meaning ascribed to it in Section 11.

 

    12

     

    

 

Loan Agreement

 

  

	SBA	shall mean the Swiss Banking Act of 8 November 1934, as amended.
	 	 
	Section	shall mean a section of this Agreement. 
	 	 
	Share(s)	shall have the meaning given in Section A of the Preamble.
	 	 
	Transaction	shall have the meaning given in Section D of the Preamble.
	 	 
	Transaction Closing	shall mean the closing of the share capital increase contemplated by the Transaction. 

 

 

13Exhibit 10.29

 

Certain personally identifiable information contained
in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K.

 

Amendment
to the Loan Agreement dated as of October 15, 2021

 

of January 18, 2022

 

between

 

		1.	Biotechnology Value Fund, L.P.

44 Montgomery Street, 40th
Floor

San Francisco, CA 94104, USA

[***]

(hereinafter
“Lender 1”)

 

		2.	Biotechnology Value Fund II, L.P.

44 Montgomery
Street, 40th Floor

San Francisco,
CA 94104, USA

[***]

(hereinafter “Lender
2”)

 

		3.	Biotechnology Value Trading Fund OS, L.P.

PO Box 309 Ugland House,
Grand Cayman

KY1-1104, Cayman
Islands

[***]

(hereinafter “Lender
3”)

 

(each a “Lender”
and collectively the “Lenders”)

 

and

 

		4.	MoonLake Immunotherapeutics AG

Dorfstrasse 29

6300 Zug, Switzerland

		[***]	

(hereinafter
the “Borrower”)

 

(the Lenders, the Borrower each a
“Party” and collectively the “Parties”)

 

     

     

    

 

Amendment to the
Loan Agreement dated as of October 15, 2021

 

TAble of contents

 

	Preamble	3
	 	 
	1.	Definitions	3
	 	 	 
	2.	Amendment Section 6 (Term and Repayment) of the Loan Agreement	3
	 	 	 
	3.	Continuity	4
	 	 	 
	4.	Term of this Amendment Agreement	4
	 	 	 
	5.	Miscellaneous	4
	 	 	 
	6.	Applicable law and jurisdiction	4

 

    2

     

    

 

Amendment to the
Loan Agreement dated as of October 15, 2021

 

		Preamble	

 

		A.	On October 15, 2021, the Parties entered into a Loan Agreement regarding certain loans in the total amount
of USD 15,000,000 (the “Loan Agreement”).

 

		B.	The Loans (as defined in the Loan Agreement) granted under the Loan Agreement were granted for a fixed
period of time until the Maturity Date (as defined in the Loan Agreement).

 

		C.	The Parties intend to amend the Maturity Date to the earlier of (i) the Transaction Closing (as defined
in the Loan Agreement) and (ii) March 31, 2022, under the terms and conditions set out in this agreement (the “Amendment Agreement”).

 

			Now, therefore, the Parties agree as follows:

 

		1.	Definitions

 

			Capitalized terms used in this Amendment Agreement shall have the respective meanings as set forth
                                                                               in the Loan Agreement.

 

		2.	Amendment Section 6 (Term and Repayment) of the Loan Agreement

 

			The Parties agree to replace Section 6 of the Loan Agreement in its entirety with the following
                                                                               section:

 

			6. 	TERM AND REPAYMENT

 

			The Loans granted hereunder are granted for a fixed period of time until the earlier of (i) as
                                                                               soon as practicable after the Transaction Closing, but no later than two (2) business days, and (ii) March 31, 2022 (the
                                                                               “Maturity Date”).

 

			 The Loans may be repaid in whole or in part by the Borrower at any time on or prior to
                                                                               the Maturity Date.

 

    3

     

    

 

Amendment to the
Loan Agreement dated as of October 15, 2021

 

		3.	Continuity

 

			The existing provisions of the Loan Agreement shall, except
as amended in this Amendment Agreement, continue in full force and effect, and shall be read and construed as one document together with
this Amendment Agreement.

 

		4.	Term of this Amendment Agreement

 

			This Amendment Agreement shall enter into force upon signature by all Parties and shall
                                                                               automatically end upon termination of the Loan Agreement.

 

		5.	Miscellaneous

 

			Section 12 of the Loan Agreement shall apply to this Amendment Agreement.

 

		6.	Applicable law and jurisdiction

 

			This Amendment Agreement shall in all respects be governed by and construed in accordance with Swiss
                                                                               law under the exclusion of its private international law provisions and international treaties.

 

			Any dispute, controversy or claim arising out of, or in relation to, this con-tract, including the
                                                                               validity, invalidity, breach, or termination thereof, shall be subject to the exclusive jurisdiction of the courts of Zug, Canton of
                                                                               Zug, Switzerland.

 

[signature page to follow]

 

    4

     

    

 

Amendment to the
Loan Agreement dated as of October 15, 2021

 

	Lender 1	 
	 	 
	Signature: 	/s/ Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	Chief Executive Officer BVF I GP LLC, itself General Partner of Biotechnology Value Fund, L.P.	 

 

	Lender 2	 	 
	 	 	 
	Signature: 	/s/ Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P.	 

 

	Lender 3	 	 
	 	 	 
	Signature: 	/s/ Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value Trading Fund OS, L.P.	 

 

	Borrower	 
	 	 
	MoonLake Immunotherapeutics AG	 
	 	 
	Signature: 	/s/ Jorge Santos da Silva	 
	Name:	Jorge Santos da Silva	 
	Title:	CEO	 
	 	 	 
	Signature:	/s/ Matthias Bodenstedt	 
	Name:	Matthias Bodenstedt	 
	Title:	CFO	 

 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]